Stocks and Investing Stocks and Investing
Wed, April 6, 2022
Tue, April 5, 2022
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022

Liisa Bayko Maintained (VRTX) at Buy with Increased Target to $278 on, Apr 1st, 2022


Published on 2024-10-27 20:16:12 - WOPRAI, Liisa Bayko
  Print publication without navigation


Liisa Bayko of Evercore ISI Group, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $265 to $278 on, Apr 1st, 2022.

Liisa has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 2 agree with Liisa's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Thursday, March 31st, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 6 analyists that currently disagree with Liisa


  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $270 on, Thursday, December 9th, 2021
  • Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021